Pro-Dex, Inc. (PDEX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Pro-Dex, Inc. (PDEX) Healthcare & Pipeline Overview

Pro-Dex, Inc. specializes in designing and manufacturing powered surgical instruments for medical device OEMs, focusing on orthopedic, thoracic, and craniomaxillofacial applications, with a strong commitment to quality and regulatory compliance.

What Is the Investment Thesis for PDEX?

With a market capitalization of $191M and a P/E ratio of 14.18, the company demonstrates solid profitability, evidenced by a profit margin of 16.1%. Growth catalysts include the increasing demand for powered surgical instruments in orthopedic and thoracic surgeries, which are projected to expand as the global healthcare market grows. Additionally, Pro-Dex’s consulting services enhance customer loyalty and open new revenue streams. The company’s focus on regulatory compliance and quality assurance further strengthens its competitive edge. However, potential risks include market fluctuations and regulatory challenges that could impact operational efficiency. Overall, Pro-Dex's robust product offerings and commitment to innovation position it well for sustained growth in the evolving healthcare landscape.

Based on FMP financials and quantitative analysis

PDEX Key Highlights

Market capitalization of $191M reflects a solid position in the medical instruments sector.

• P/E ratio of 14.18 indicates attractive valuation relative to earnings.
• Profit margin of 16.1% showcases operational efficiency and profitability.
• Gross margin of 27.8% exceeds industry averages, highlighting effective cost management.
• Beta of -0.11 suggests lower volatility compared to the broader market.

Who Are PDEX's Competitors?

PDEX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PDEX's Key Strengths?

Established brand with a strong reputation in the medical instruments sector.

• Diverse product offerings that cater to multiple surgical markets.
• Strong profit margins indicating effective cost management.
• Expertise in regulatory compliance enhances market credibility.

What Are PDEX's Weaknesses?

Limited market presence compared to larger competitors.

• Dependence on a narrow range of products for revenue generation.
• No dividend yield may deter income-focused investors.
• Relatively small workforce may limit production capacity.

What Could Drive PDEX Stock Higher?

PDEX catalyst: Expansion of product lines to include more advanced surgical instruments tailored for minimally invasive procedures.

• Continuous improvement in operational efficiency leading to sustained profit margins above industry averages.
• Strategic partnerships with key OEMs to co-develop innovative surgical solutions.
• Increasing demand for consulting services as healthcare regulations become more complex.
• Geographic expansion efforts targeting emerging markets with growing healthcare infrastructure.

What Are the Key Risks for PDEX?

Insider selling — insiders were net sellers of roughly $1.4M recently.

• Regulatory changes that could affect product approval processes and timelines.
• Intense competition from larger medical device manufacturers impacting market share.
• Economic fluctuations that may reduce healthcare spending and impact sales.
• Dependence on a limited range of products may expose the company to market volatility.

What Are the Growth Opportunities for PDEX?

• Growth opportunity 1: The global orthopedic surgical instruments market is projected to reach $45 billion by 2028, growing at a CAGR of 6.5%. Pro-Dex can capitalize on this growth by expanding its product offerings and enhancing its marketing strategies to reach more OEMs in this sector.
• Growth opportunity 2: The increasing trend towards minimally invasive surgeries is driving demand for advanced surgical instruments. Pro-Dex's focus on developing innovative, multi-functional surgical drivers and shavers positions it to capture a larger market share in this growing segment, expected to grow at a CAGR of 7% over the next five years.
• Growth opportunity 3: Expanding its consulting services can open new revenue streams. With healthcare regulations becoming more complex, Pro-Dex can leverage its expertise to offer comprehensive consulting solutions, targeting a market estimated at $10 billion by 2027.
• Growth opportunity 4: Strategic partnerships with leading medical device manufacturers can enhance Pro-Dex's market presence. Collaborations can lead to co-development of new technologies, tapping into the growing demand for innovative surgical solutions, which is projected to increase by 5% annually.
• Growth opportunity 5: Geographic expansion into emerging markets presents significant potential. As healthcare infrastructure improves in regions like Asia-Pacific and Latin America, Pro-Dex can establish a foothold, targeting a market anticipated to grow at a CAGR of 8% through 2030.

What Are PDEX's Competitive Advantages?

• Strong focus on regulatory compliance and quality assurance.
• Established reputation in the orthopedic and surgical instruments market.
• Diverse product offerings that cater to multiple surgical specialties.
• Expertise in engineering and consulting services enhances customer loyalty.
• Long-standing relationships with OEMs provide competitive advantages.

What Does PDEX Do?

Founded in 1978, Pro-Dex, Inc. has established itself as a pivotal player in the healthcare sector, specifically within the medical instruments and supplies industry. Headquartered in Irvine, California, the company designs, develops, and manufactures powered surgical instruments tailored for original equipment manufacturers (OEMs) in the medical device field. Pro-Dex’s product portfolio includes autoclavable, battery-powered, and electric multi-function surgical drivers and shavers, which are predominantly utilized in orthopedic, thoracic, and craniomaxillofacial surgeries. Over the years, the company has evolved to not only focus on surgical instruments but also to provide engineering, quality, and regulatory consulting services, thereby enhancing its value proposition to clients. Additionally, Pro-Dex manufactures and sells rotary air motors to various industries, diversifying its revenue streams. With a workforce of 146 employees, the company emphasizes innovation and quality, maintaining a profit margin of 16.1% and a gross margin of 27.8%. Pro-Dex's commitment to excellence and compliance with regulatory standards positions it favorably within a competitive landscape, catering to a global market of medical device manufacturers.

What Products and Services Does PDEX Offer?

• Design and manufacture powered surgical instruments for medical device OEMs.
• Offer a range of autoclavable, battery-powered, and electric surgical drivers and shavers.
• Provide engineering, quality, and regulatory consulting services to enhance compliance.
• Manufacture and sell rotary air motors for various industrial applications.
• Focus on orthopedic, thoracic, and craniomaxillofacial surgical markets.
• Commit to high standards of quality and regulatory compliance in all products.

How Does PDEX Make Money?

• Generate revenue through the sale of powered surgical instruments to OEMs.
• Offer consulting services that provide additional revenue streams.
• Manufacture rotary air motors for diverse industrial applications.
• Focus on high-margin products to enhance profitability.
• Leverage strong relationships with OEMs to ensure repeat business.

What Industry Does PDEX Operate In?

The medical instruments and supplies industry is experiencing significant growth, driven by advancements in surgical technology and an increasing number of surgical procedures globally. The orthopedic market, in particular, is expected to expand as the aging population requires more surgical interventions. Pro-Dex, Inc. is well-positioned within this landscape, focusing on powered surgical instruments that meet the evolving needs of healthcare providers. The competitive landscape includes various players, but Pro-Dex differentiates itself through its commitment to quality and regulatory expertise, which are critical in this highly regulated industry.

Who Are PDEX's Key Customers?

• Original equipment manufacturers (OEMs) in the medical device sector.
• Healthcare providers requiring advanced surgical instruments.
• Industries needing rotary air motors for various applications.
• Regulatory bodies seeking compliance consulting services.
• Surgical teams in hospitals and clinics using powered instruments.

Over the past six months, Pro-Dex, Inc. insiders filed 14 SEC Form 4 transactions — 10 sales and 4 purchases. On net that is roughly 10K shares acquired (about $1.4M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Pro-Dex, Inc.

Revenue for Pro-Dex, Inc. came in at $20.4M during Q4 FY2026, a 2.3% improvement versus the preceding quarter. The company recorded net income of $2.9M, with diluted EPS of $0.86. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, PDEX averaged $1.03 in diluted EPS.

PDEX Valuation & Market Position

With a $191M market cap, Pro-Dex, Inc. sits in the micro-cap segment of the market. Relative to its peer group, PDEX's quantitative score of 81/100 is roughly in line with the peer average of 76/100.

Return on equity for Pro-Dex, Inc. stands at 29.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 16.0%, showing how much profit it generates from its asset base. PDEX trades at a trailing price-to-earnings ratio of 14.18, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 3.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.67 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.0%, the inverse of the P/E and a quick read on earnings relative to price.

Pro-Dex, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 7.49 places it in the safe zone, indicating low near-term bankruptcy risk.

Pro-Dex, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 77.4% above estimates on average.

Company Profile

Pro-Dex, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Richard Lee Van Kirk Jr.. PDEX has traded publicly since 1986.

PDEX Financials

PDEX Latest News

PDEX Analyst Consensus

PDEX MoonshotScore

Pro-Dex, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources